Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide Re-Treatment in mCRPC
NCT02441517Phase 4Terminated
- Sponsor
- Astellas Pharma
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of enzalutamide in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Astellas Pharma. Primary endpoint: Radiographic Progression Free Survival at 17 months. Started Oct 2015; status: terminated.
02
Drugs
enzalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02441517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02441517.